Call to Include More People Aged Over 60 in Clinical Trials

A new report from the International Longevity Centre (ILC), a specialist think tank on longevity, urges action to ensure medicines are tested on the people they are supposed to help.

The Trial and error report urges regulators, pharmaceutical companies and researchers to prioritise age diversity at all stages of the clinical trial process.

Older people are prescribed more medications more frequently than other age groups. Yet they are consistently underrepresented in the trials testing the safety and efficacy of medicines. Between 2006 to 2016, 60% of all community prescriptions in England were dispensed to people aged over 60. A 2014 study found that a third of trials excluded people purely on the basis of age; another study in the US from 2022 found that trials that were inclusive of older adults still did not recruit the “oldest old” in sufficient numbers. Some steps have been taken in the right direction since then, but ILC argues that the action being taken does not reflect the scale of the problem.

Based on in-depth expert interviews and a roundtable discussion, this new report unpicks why age diversity lags in trial design. Among the barriers to age parity, the report finds that added costs (in terms of clinical time and resources) of recruiting older patients was prohibitive to inclusion, particularly since many older patients have existing health conditions. Another barrier is arbitrary exclusion of participants on the basis of their age – this could be direct in trial protocols, or indirect through the decisions of the trial team to recruit (or not recruit) age-diverse cohorts. The ILC report suggests practical steps towards improving age diversity in trial cohorts. For example, age-related data is not consistently gathered across all trials, particularly those testing medications for conditions not associated with ageing. Doing so would help us better understand where older patients’ participation is lacking, and which trials successfully include significant numbers of older people.

Esther McNamara, Senior Health Policy Lead at ILC and author of the report explains:
“This issue has rumbled on for many years; regulators, patient groups, researchers and pharmaceutical companies agree that a concerted effort is required to include more older people in trials. These are the people who can ensure that the best treatments are found for the conditions that affect them most. We spoke with a range of expert stakeholders to reach conclusions and make recommendations in our report which, if implemented, could support huge changes that better serve older patients.”

“These new initiatives by the US and UK government agencies are timely, but we urgently need guidelines for clinical trials to put age diversity on a par with gender and ethnicity. We make recommendations in this report that affect stakeholders at all stages of the trial process. Only once these changes have been made, will clinical trials generate the evidence that older patients deserve when they are prescribed medicines.”

Emma Thorp, Chief Commercial Officer at RBW Consulting, a certified B Corp company specialising in life science search and recruitment who provided support for the project as part of their ongoing CSR programme said:
“We are proud to have partnered with the ILC on this project. Against the backdrop of the United Nations decade of healthy ageing, it felt like the right time to drill down into the needs of older people as part of the movement to make clinical trials more representative.

“It’s our hope that this work will support our clients and the industry in general with inclusive trial design. The more we can identify and share practical solutions, the more progress we will make, and our hope is that this work will sit alongside the excellent efforts of others to make real change happen.”

Miles Witham: University of Newcastle, Professor of Trials for Older People
“This report reinforces the fact that we can’t tackle this issue with isolated initiatives – we need a broad-spectrum approach right across regulators, researchers, industry and patients in order to bring about the required change.”

The full report can be downloaded here











COTS 2024